Neogen Corp (NEOG)

$17.33

+0.31

(+1.82%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $17.13
    $17.60
    $17.33
    downward going graph

    1.18%

    Downside

    Day's Volatility :2.67%

    Upside

    1.51%

    downward going graph
  • $11.46
    $24.10
    $17.33
    downward going graph

    33.87%

    Downside

    52 Weeks Volatility :52.45%

    Upside

    28.09%

    downward going graph

Returns

PeriodNeogen CorpSector (Health Care)Index (Russel 2000)
3 Months
40.2%
6.5%
0.0%
6 Months
5.45%
7.1%
0.0%
1 Year
-24.62%
9.8%
0.0%
3 Years
-60.82%
14.2%
-20.2%

Highlights

Market Capitalization
3.6B
Book Value
$14.53
Earnings Per Share (EPS)
0.02
PE Ratio
841.0
PEG Ratio
0.66
Wall Street Target Price
20.0
Profit Margin
0.17%
Operating Margin TTM
5.26%
Return On Assets TTM
1.79%
Return On Equity TTM
0.05%
Revenue TTM
929.2M
Revenue Per Share TTM
4.29
Quarterly Revenue Growth YOY
4.8%
Gross Profit TTM
409.2M
EBITDA
246.8M
Diluted Eps TTM
0.02
Quarterly Earnings Growth YOY
-0.86
EPS Estimate Current Year
0.46
EPS Estimate Next Year
0.54
EPS Estimate Current Quarter
0.14
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Neogen Corp(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 15.41%

Current $17.33
Target $20.00

Company Financials

FY18Y/Y Change
Revenue
402.3M
↑ 11.24%
Net Income
63.1M
↑ 44.19%
Net Profit Margin
15.7%
↑ 3.59%
FY19Y/Y Change
Revenue
414.2M
↑ 2.97%
Net Income
60.2M
↓ 4.7%
Net Profit Margin
14.53%
↓ 1.17%
FY20Y/Y Change
Revenue
418.2M
↑ 0.96%
Net Income
59.5M
↓ 1.16%
Net Profit Margin
14.22%
↓ 0.31%
FY21Y/Y Change
Revenue
468.5M
↑ 12.03%
Net Income
60.9M
↑ 2.37%
Net Profit Margin
13.0%
↓ 1.22%
FY22Y/Y Change
Revenue
527.2M
↑ 12.53%
Net Income
48.3M
↓ 20.65%
Net Profit Margin
9.16%
↓ 3.84%
FY23Y/Y Change
Revenue
822.4M
↑ 56.01%
Net Income
-22.9M
↓ 147.34%
Net Profit Margin
-2.78%
↓ 11.94%
Q4 FY22Q/Q Change
Revenue
230.0M
↑ 73.81%
Net Income
-41.8M
↓ 903.24%
Net Profit Margin
-18.19%
↓ 22.13%
Q1 FY23Q/Q Change
Revenue
218.3M
↓ 5.12%
Net Income
8.2M
↓ 119.57%
Net Profit Margin
3.75%
↑ 21.94%
Q2 FY23Q/Q Change
Revenue
241.8M
↑ 10.79%
Net Income
5.6M
↓ 31.97%
Net Profit Margin
2.3%
↓ 1.45%
Q3 FY23Q/Q Change
Revenue
229.0M
↓ 5.3%
Net Income
1.5M
↓ 73.03%
Net Profit Margin
0.66%
↓ 1.64%
Q4 FY23Q/Q Change
Revenue
229.6M
↑ 0.28%
Net Income
-3.5M
↓ 332.0%
Net Profit Margin
-1.52%
↓ 2.18%
Q1 FY24Q/Q Change
Revenue
228.8M
↓ 0.36%
Net Income
-2.0M
↓ 42.01%
Net Profit Margin
-0.88%
↑ 0.64%
FY18Y/Y Change
Total Assets
618.0M
↑ 16.96%
Total Liabilities
57.8M
↑ 2.09%
FY19Y/Y Change
Total Assets
695.7M
↑ 12.58%
Total Liabilities
57.8M
↑ 0.01%
FY20Y/Y Change
Total Assets
797.2M
↑ 14.58%
Total Liabilities
72.0M
↑ 24.49%
FY21Y/Y Change
Total Assets
920.2M
↑ 15.43%
Total Liabilities
79.8M
↑ 10.85%
FY22Y/Y Change
Total Assets
992.9M
↑ 7.9%
Total Liabilities
105.6M
↑ 32.25%
FY23Y/Y Change
Total Assets
4.6B
↑ 358.69%
Total Liabilities
1.4B
↑ 1245.47%
Q4 FY22Q/Q Change
Total Assets
4.6B
↑ 366.64%
Total Liabilities
1.5B
↑ 1454.09%
Q1 FY23Q/Q Change
Total Assets
4.5B
↓ 1.15%
Total Liabilities
1.4B
↓ 4.92%
Q2 FY23Q/Q Change
Total Assets
4.6B
↑ 1.01%
Total Liabilities
1.4B
↑ 2.68%
Q3 FY23Q/Q Change
Total Assets
4.6B
↑ 0.15%
Total Liabilities
1.4B
↓ 0.37%
Q4 FY23Q/Q Change
Total Assets
4.6B
↑ 0.91%
Total Liabilities
1.5B
↑ 2.82%
Q1 FY24Q/Q Change
Total Assets
4.6B
↓ 0.43%
Total Liabilities
1.4B
↓ 1.27%
FY18Y/Y Change
Operating Cash Flow
69.1M
↑ 14.69%
Investing Cash Flow
-83.1M
↑ 33.71%
Financing Cash Flow
22.8M
↓ 8.9%
FY19Y/Y Change
Operating Cash Flow
63.8M
↓ 7.65%
Investing Cash Flow
-119.1M
↑ 43.41%
Financing Cash Flow
13.9M
↓ 39.14%
FY20Y/Y Change
Operating Cash Flow
85.9M
↑ 34.52%
Investing Cash Flow
-88.8M
↓ 25.48%
Financing Cash Flow
29.4M
↑ 111.56%
FY21Y/Y Change
Operating Cash Flow
81.1M
↓ 5.58%
Investing Cash Flow
-105.6M
↑ 18.9%
Financing Cash Flow
33.5M
↑ 14.08%
FY22Y/Y Change
Operating Cash Flow
68.0M
↓ 16.09%
Investing Cash Flow
-97.2M
↓ 7.9%
Financing Cash Flow
6.8M
↓ 79.69%
FY23Y/Y Change
Operating Cash Flow
41.0M
↓ 39.7%
Investing Cash Flow
201.0M
↓ 306.77%
Financing Cash Flow
-118.1M
↓ 1833.17%
Q4 FY22Q/Q Change
Operating Cash Flow
-18.7M
↑ 32.4%
Investing Cash Flow
93.0M
↑ 13.92%
Financing Cash Flow
-79.3M
↓ 8858.12%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.1M
↓ 8.85%
Investing Cash Flow
6.9M
↓ 92.61%
Financing Cash Flow
-40.0M
↓ 49.56%
Q2 FY23Q/Q Change
Operating Cash Flow
91.0M
↓ 632.93%
Investing Cash Flow
6.9M
↑ 0.0%
Financing Cash Flow
252.0K
↓ 100.63%
Q3 FY23Q/Q Change
Operating Cash Flow
23.0M
↓ 74.71%
Investing Cash Flow
-8.7M
↓ 226.29%
Financing Cash Flow
1.1M
↑ 321.43%

Technicals Summary

Sell

Neutral

Buy

Neogen Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neogen Corp
Neogen Corp
6.44%
5.45%
-24.62%
-60.82%
-51.48%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.67%
-10.34%
-15.37%
-31.35%
65.77%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.42%
3.05%
5.07%
-10.16%
94.22%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
6.51%
8.62%
3.5%
12.36%
106.99%
Danaher Corp.
Danaher Corp.
6.51%
15.92%
1.97%
-6.92%
89.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
10.0%
7.5%
0.14%
-6.07%
45.29%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neogen Corp
Neogen Corp
841.0
841.0
0.66
0.46
0.0
0.02
NA
14.53
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.67
45.67
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.63
31.63
2.7
5.2
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.71
0.14
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
48.76
48.76
3.13
6.99
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.13
30.13
1.33
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neogen Corp
Neogen Corp
Buy
$3.6B
-51.48%
841.0
0.17%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.8B
65.77%
45.67
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.9B
94.22%
31.63
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.4B
106.99%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.9B
89.83%
48.76
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.3B
45.29%
30.13
9.39%

Insights on Neogen Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 229.62M → 228.81M (in $), with an average decrease of 0.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -3.48M → -2.02M (in $), with an average increase of 72.5% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 29.7%

  • Vs TMO

    In the last 3 years, Neogen Corp has experienced a drawdown of -60.8%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 50.6%

Institutional Holdings

  • BlackRock Inc

    11.33%

  • Vanguard Group Inc

    9.10%

  • NORGES BANK

    8.40%

  • Select Equity Group LP

    5.82%

  • Baillie Gifford & Co Limited.

    5.44%

  • State Street Corporation

    3.49%

Company Information

neogen corporation develops and markets products dedicated to food and animal safety. the company’s food safety division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. neogen’s animal safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants and rodenticides.

Organization
Neogen Corp
Employees
2640
CEO
Mr. John Edward Adent
Industry
Health Technology

Discover More

FAQs